Clinical Trials Page  
  L-MARC Home Page  ::  
   
 
Hypertension Clinical Trials

 

PHARMACODYNAMIC EQUIVALENCE STUDY OF RAMIPRIL 10 MG AND ATORVASTATIN 40 MG ADMINISTERED AS A CARDIOVASCULAR FIXED DOSE COMBINATION PILL AAR AS COMPARED TO MONOTHERAPY WITH THE REFERENCE PRODUCTS ALTACE 10 MG AND LIPITOR 40 MG
(PRINCIPAL INVESTIGATOR, 2016)

THE EFFECT OF LY2409021 ON BLOOD PRESSURE AND PULSE RATE, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MONITORING, IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR 2014)

PERINDOPRIL AMLODIPINE FOR THE TREATMENT OF HYPERTENSION (PATH): A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF A FIXED DOSE COMBINATION OF PERINDOPRIL ARGININE PLUS AMLODIPINE BESYLATE VERSUS PERINDOPRIL ERBUMINE AND AMLODIPINE BESYLATE IN SUBJECTS WITH ESSENTIAL HYPERTENSION
(PRINCIPAL INVESTIGATOR 2012)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 8-WEEK STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NEBIVOLOL AND VALSARTAN GIVEN AS A FEXED DOSE COMBINATION IN PATIENTS WITH STAGE 1 OR 2 HYPERTENTION
(PRINCIPAL INVESTIGATOR 2011)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF NEBIVOLOL IN YOUNGER PATIENTS (18 - 54 YEARS) WHO HAVE STAGE 1 OR 2 ESSENTIAL HYPERTENSION
(PRINCIPAL INVESTIGATOR 2011)

A RANDOMIZED, UNBLINDED, SINGLE RESEARCH SITE, COMPARATOR STUDY OF RAISINS VERSUS ALTERNATIVE SNACKS ON CARDIOVASCULAR RISK FACTORS IN GENERALLY HEALTHY SUBJECTS
(PRINCIPAL INVESTIGATOR 2011)

A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECTS OF FIRST LINE TREATMENT WITH A FREE COMBINATION OF NEBIVOLOL AND LISINOPRIL COMPARED WITH PLACEBO AND THE MONOTHERAPY COMPONENTS ON BLOOD PRESSURE IN PATIENTS WITH STAGE 2 DIASTOLIC HYPERTENSION
(PRINCIPAL INVESTIGATOR 2010)

A RANDOMISED, DOUBLE-BLIND, DOUBLE DUMMY, ACTIVE CONTROLLED, PARALLEL GROUP, FORCED TITRATION STUDY TO COMPARE THE FIXED-DOSE COMBINATION OF TELMISARTAN 80 MG PLUS HYDROCHLOROTHIAZIDE 25 MG (T80/HCTZ25) VERSUS TELMISARTAN 80 MG (T80) MONOTHERAPY AS FIRST LINE THERAPY IN PATIENTS WITH GRADE 2 OR GRADE 3 HYPERTENSION (SBP>=160 MM/HG AND DBP >=100MM HG)
(PRINCIPAL INVESTIGATOR 2010)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, EXPLORATORY, 28-DAY STUDY TO EXAMINE THE EFFECTS OF AR9281 ON BLOOD PRESSURE AND GLUCOSE TOLERANCE IN PATIENTS WITH MILD TO MODERATE HYPERTENSION AND IMPAIRED GLUCOSE TOLERANCE
(PRINCIPAL INVESTIGATOR 2009)

A RANDOMISED, DOUBLE-BLIND, DOUBLE DUMMY, ACTIVE CONTROLLED, PARALLEL GROUP, FORCED TITRATION STUDY TO COMPARE THE FIXED-DOSE COMBINATION OF TELMISARTAN 80 MG PLUS HYDROCHLOROTHIAZIDE 25 MG (T80/HCTZ24) VERSUS TELMISARTAN 80 MG (T80) MONOTHERAPY AS FIRST LINE THERAPY IN PATIENTS WITH SEVERE HYPERTENSION
(PRINCIPAL INVESTIGATOR 2009)

A PHASE 3, DOUBLE-BLIND, RANDOMIZED, EFFICACY AND SAFETY STUDY COMPARING THE TAK-491 PLUS CHLORTHALIDONE FIXED-DOSE COMBINATION VS BENICAR HCT (OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE IN SUBJECTS WITH MODERATE TO SEVERE ESSENTIAL HYPERTENSION
(PRINCIPAL INVESTIGATOR 2009)

A WORLDWIDE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MK-0736 WHEN ADDED TO ONGOING THERAPY WITH ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITOR OR ANGIOTENSIN RECEPTOR BLOCKER (ARB) IN PATIENTS WITH DIABETES AND HYPERTENSION
(PRINCIPAL INVESTIGATOR 2009)

A DOUBLE-BLIND, RANDOMIZED, PARALLEL, EFFICACY STUDY EVALUATING LOSARTAN POTASSIUM ALONE OR IN COMBINATION WITH HYDROCHLOROTHIAZIDE VERSUS PLACEBO IN OBESE PATIENTS WITH ELEVATED SYSTOLIC AND DIASTOLIC BLOOD PRESSURE
(PRINCIPAL INVESTIGATOR 2006)

A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, FACTORIAL DESIGN TRIAL TO ASSESS THE EFFICACY AND SAFETY OF UP TO SIX WEEKS TREATMENT WITH 20 MG, 40 MG, OR 80 MG QD DOSES CARVEDILOL CONTROLLED RELEASE FORMULATION (COREG CR) OR 10 MG, 20 MG, OR 40 MG QD DOSES OF LISINOPRIL (ZESTRIL) OR A COMBINATION OF ONE OF THE DOSES OF EACH MEDICATION
(PRINCIPAL INVESTIGATOR 2006)

A DOUBLE-BLIND, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS OF THE COMBINATION OF VALSARTAN AND AMLODIPINE IN HYPERTENSIVE PATIENTS NOT CONTROLLED ON MONOTHERAPY.
(PRINCIPAL INVESTIGATOR 2006)

A DOUBLE-BLIND, RANDOMIZED, PARALLEL, EFFICACY STUDY WITH LOSARTAN POTASSIUM ALONE OR IN COMBINATION WITH HYDROCHLOROTHIAZIDE VERSUS PLACEBO IN OBESE PATIENTS WITH ELEVATED SYSTOLIC AND DIASTOLIC BLOOD PRESSURE
(PRINCIPAL INVESTIGATOR 2006)

A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, 4X4 FACTORIAL DESIGN TRIAL TO EVALUATE TELMISARTAN 20, 40, AND 80 MG TABLETS IN COMBINATION WITH AMLODIPINE 2.5, 5, AND 10MG CAPSULES AFTER EIGHT WEEKS OF TREATMENT IN PATIENTS WITH STAGE I OR II HYPERTENSION, WITH AN ABPM SUB-STUDY.
(PRINCIPAL INVESTIGATOR 2005)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FORCED-TITRATION, PHASE IV STUDY COMPARING TELMISARTAN 80 MG + HYDROCHLOROTHIAZIDE 25 MG VERSUS VALSARTAN 160 MG + HYDROCHLOROTHIAZIDE 25 MG TAKEN ORALLY FOR EIGHT WEEKS IN PATIENTS WITH STAGE 1 OR STAGE 2 HYPERTENSION
(PRINCIPAL INVESTIGATOR 2005)

EFFECT OF ALAGEBRIUM (ALT-711) IN COMBINATION WITH FIXED-DOSE HYDROCHLOROTHIAZIDE THERAPY ON SYSTOLIC BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
(PRINCIPAL INVESTIGATOR 2004)

A RANDOMIZED, DOUBLE-BLIND, PARALLEL-FILTER STUDY TO EVALUATE THE ANTIHYPERTENSIVE EFFICACY AND SAFETY OF LOSARTAN-HCTZ COMBINATION AS COMPARED TO LOSARTAN MONOTHERAPY IN PATIENTS WITH ESSENTIAL HYPERTENSION
(PRINCIPAL INVESTIGATOR 2004)

A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP FACTORIAL STUDY OF METOPROLOL SUCCINATE EXTENDED-RELEASE TABLETS (TOPROL-XL), HYDROCHLOROTHIAZIDE AND THEIR COMBINATION PATIENTS WITH ESSENTIAL HYPERTENSION.
(PRINCIPAL INVESTIGATOR 2003 - 2004)

THE EFFICACY AND SAFETY OF AVALIDE 150/12.5 MG AND AVALIDE 300/25 MG IN PATIENTS WITH HYPERTENSION UNCONTROLLED ON MONOTHERAPY.
(PRINCIPAL INVESTIGATOR 2003 - 2004)

A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, FORCED-TITRATION, COMPARISON OF MICARDIS HCT (TELEMISARTAN 80 MG / HYDROCHLOROTHIAZIDE 25MG) VERSUS DIOVAN HCT (VALSARTAN 160MG / HYDROCHLOROTHIAZIDE 25 MG) USING SEATED TROUGH CUFF BLOOD PRESSURE IN PATIENTS WITH STAGE 1 AND STAGE 2 HYPERTENSION
(PRINCIPAL INVESTIGATOR 2003 - 2004)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFECTS OF CELECOXIB 200 MG QD, CELECOXIB 200 MG BID, AND PLACEBO IN PATIENTS WITH TREATED HYPERTENSION
(PRINCIPAL INVESTIGATOR 2001)

DOUBLE -BLIND, RANDOMIZED, PARALLEL GROUP COMPARISON STUDY OF THE SAFETY OF CELECOXIB VS ROFECOXIB IN TREATED HYPERTENSIVE PATIENTS WITH OSTEOARTHRITIS (SUCCESS VII)
(PRINCIPAL INVESTIGATOR, 2000 - 2001)

OMAPATRILAT IN PERSONS WITH ENHANCED RISK OF ATHEROSCLEROTIC EVENTS: THE "OPERA" STUDY
(PRINCIPAL INVESTIGATOR, 2000 - 2001)

OMAPATRILAT CARDIOVASCULAR TREATMENT ASSESSMENT VERSUS ENALAPRIL (OCTAVE)
(PRINCIPAL INVESTIGATOR, 2000 - 2001)

OMAPATRILAT CARDIOVASCULAR TREATMENT ASSESSMENT VERSUS ENALAPRIL (OCTAVE) - PROSPECTIVE NESTED CASE-CONTROLLED STUDY OF POTENTIAL RISK FACTORS FOR ANGIOEDEMA IN SUBJECTS EXPOSED TO OMAPATRILAT OR ENALAPRIL
(PRINCIPAL INVESTIGATOR, 2000- 2001)

A RANDOMIZED, DOUBLE-BLIND SAFETY AND EFFICACY STUDY OF LOSARTAN PLUS HYDROCHLOROTHIAZIDE VERSUS LOSARTAN AS FIRST-LINE THERAPY AFTER 6 WEEKS IN PATIENTS WITH SEVERE HYPERTENSION
(PRINCIPAL INVESTIGATOR, 2000 - 2001)

DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP COMPARISON STUDY OF THE SAFETY OF CELECOXIB VS ROFECOXIB IN HYPERTENSIVE PATIENTS WITH PERIPHERAL OSTEOARTHRITIS TAKING ANTIHYPERTENSIVE MEDICATIONS (SUCCESS-VI)
(PRINCIPAL INVESTIGATOR, 1999 - 2000)

A RANDOMIZED, DOUBLE-BLIND, AMLODIPINE- AND LOSARTAN-CONTROLLED STUDY OF OMAPATRILAT IN SUBJECTS WITH MILD TO MODERATE HYPERTENSION
(PRINCIPAL INVESTIGATOR, 1999 - 1999)

A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, INPATIENT STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND ANTIHYPERTENSIVE EFFICACY OF A MULTIPLE-DOSE REGIMEN OF L-7537,037 IN AFRICAN AMERICAN PATIENTS WITH MILD-TO-MODERATE HYPERTENSION
(PRINCIPAL INVESTIGATOR, 1998 - 1999)

THE EFFICACY AND SAFETY OF OMAPATRILAT ADDED TO HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION IN SUBJECTS NON-RESPONSIVE TO HYDROCHLOROTHIAZIDE ALONE
(PRINCIPAL INVESTIGATOR, 1998 - 1999)

AN EVALUATION OF THE SAFETY AND EFFECTIVENESS OF AVAPRO FOR THE TREATMENT OF HYPERTENSION: A POST MARKETING SURVEILLANCE STUDY
(PRINCIPAL INVESTIGATOR, 1998)

MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP COMPARATIVE TRIAL OF THE ANTIHYPERTENSIVE ACTIVITY AND SAFETY OF IRBESARTAN AND LOSARTAN IN SUBJECTS WITH MILD-TO-MODERATE HYPERTENSION
(PRINCIPAL INVESTIGATOR, 1996 - 1997)

RANDOMIZED, DOUBLE-BLIND PARALLEL TRIAL COMPARING LOTREL AT DIFFERING DOSES COMPARED TO NIFEDIPINE GITS IN PATIENTS WITH ESSENTIAL HYPERTENSION INADEQUATELY CONTROLLED WITH NIFEDIPINE ALONE, FOLLOWED BY A SINGLE-BLIND EXTENSION OF LOTREL 5/20 MG ONCE DAILY
(PRINCIPAL INVESTIGATOR, 1996 - 1997)

A MULTIPLE DOSE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTIFACTORIAL, PARALLEL TRIAL COMPARING THE COMBINATION THERAPY OF VALSARTAN (80MG OR 160 MG) AND HYDROCHLOROTHIAZIDE (12.5 MG OR 25 MG) TO VALSARTAN MONOTHERAPY (80 MG OR 160 MG), HYDROCHLOROTHIAZIDE MONOTHERAPY (12.5 MG OR 25 MG) AND PLACEBO IN HYPERTENSIVE PATIENTS AGE 18 - 80 YEARS
(PRINCIPAL INVESTIGATOR, 1995-1996)

FACTORIAL TRIAL OF THE EFFICACY AND SAFETY OF MULTIPLE DOSAGES OF IRBESARTAN AND HCTZ IN MILD TO MODERATE HYPERTENSION "MATRIX STUDY"
(PRINCIPAL INVESTIGATOR 1994-1996)

RESEARCH COMPLETED TRIALS THE EFFICACY AND SAFETY OF IRBESARTAN ADDED TO HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION IN SUBJECTS NONRESPONSIVE TO HYDROCHLOROTHIAZIDE ALONE - "FILTER STUDY"
(PRINCIPAL INVESTIGATOR 1994-1996)

12 WEEK, OPEN-LABEL EVALUATION OF CATAPRES-TTS IN AFRICAN AMERICAN AND HISPANIC PATIENTS
(PRINCIPAL INVESTIGATOR 1994)

S.E.L.E.C.T. (SELECOR'S EFFECT LOWERING BP IN THOSE WITH ELEVATED CHOLESTEROL/TRIGLYCERIDES) STUDY
(PRINCIPAL INVESTIGATOR 1991)

L-MARC HOME PAGE